TY - JOUR
T1 - Long-term outcome of peripheral T-cell lymphomas
T2 - Ten-year follow-up of the International Prospective T-cell Project
AU - Civallero, Monica
AU - Schroers-Martin, Joseph G.
AU - Horwitz, Steven
AU - Manni, Martina
AU - Stepanishyna, Yana
AU - Cabrera, Maria Elena
AU - Vose, Julie
AU - Spina, Michele
AU - Hitz, Felicitas
AU - Nagler, Arnon
AU - Montoto, Silvia
AU - Chiattone, Carlos
AU - Skrypets, Tetiana
AU - Perez Saenz, M. Angeles
AU - Priolo, Giorgio
AU - Luminari, Stefano
AU - Lymboussaki, Athina
AU - Pavlovsky, Astrid
AU - Marino, Dario
AU - Liberati, Marina
AU - Trotman, Judith
AU - Mannina, Donato
AU - Federico, Massimo
AU - Advani, Ranjana
N1 - Publisher Copyright:
© 2024 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2024/7
Y1 - 2024/7
N2 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2–4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
AB - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2–4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
KW - T-cell lymphomas
KW - TCP1
KW - follow-up
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=85189527148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85189527148&partnerID=8YFLogxK
U2 - 10.1111/bjh.19433
DO - 10.1111/bjh.19433
M3 - Article
C2 - 38532575
AN - SCOPUS:85189527148
SN - 0007-1048
VL - 205
SP - 166
EP - 174
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -